Archean Chemical Industries (ACI) Q2 24/25 earnings summary

Executive summary

• Leadership emphasized diversification and de-risking, with R&D driving expansion into semiconductors and energy storage, while maintaining leadership in marine chemicals and industrial salt exports.

• Approved unaudited standalone and consolidated financial results for Q2 and H1 FY25, with auditor review confirming no material misstatements.

Financial highlights

• Q2 FY25 standalone revenue was INR 2,521 million, down 17% year-over-year, mainly due to logistics and weather disruptions; consolidated Q2 revenue was ₹24,045.52 lakhs.

• H1 FY25 standalone revenue was INR 4,754 million, down 28% year-over-year; consolidated H1 revenue was ₹45,314.72 lakhs, down from ₹63,355.83 lakhs in H1 FY24.

• Q2 FY25 EBITDA was INR 898 million (36% margin); H1 FY25 EBITDA was INR 1,747 million (37% margin); H1 FY25 consolidated net profit was ₹7,032.91 lakhs, down from ₹16,051.78 lakhs in H1 FY24.

• Exceptional loss of INR 401.8 million (₹4,018.27 lakhs) in Q2 FY25 due to Cyclone Asna, impacting industrial salt inventory; insurance claims initiated.

• Export markets contributed 77% of Q2 revenue and 75% of H1 revenue.

Outlook and guidance

• Bromine production targeted to exceed 20,000 MT for FY25, with next year’s guidance at 20,000–25,000 MT.

• Industrial salt volumes expected at over 1 million tons per quarter in H2, with annual guidance of 4.5 million tons, subject to weather variance.

• Focus on capacity augmentation through debottlenecking and greenfield expansion, especially in bromine derivatives.

• Management remains cautious on bromine market recovery amid global and competitive pressures.

• Insurance claim process and land lease renewal in Gujarat are ongoing.